Mirova Makes New $1.07 Million Investment in NeoGenomics, Inc. (NASDAQ:NEO)

Mirova acquired a new stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 64,935 shares of the medical research company's stock, valued at approximately $1,070,000. Mirova owned approximately 0.05% of NeoGenomics as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nordea Investment Management AB lifted its position in shares of NeoGenomics by 2.8% during the 4th quarter. Nordea Investment Management AB now owns 77,534 shares of the medical research company's stock worth $1,301,000 after purchasing an additional 2,125 shares during the last quarter. Geode Capital Management LLC increased its position in NeoGenomics by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 3,051,806 shares of the medical research company's stock worth $45,022,000 after buying an additional 36,136 shares during the period. Swiss National Bank lifted its holdings in shares of NeoGenomics by 1.0% during the fourth quarter. Swiss National Bank now owns 252,100 shares of the medical research company's stock worth $4,155,000 after buying an additional 2,600 shares during the last quarter. Jennison Associates LLC boosted its position in shares of NeoGenomics by 18.7% in the fourth quarter. Jennison Associates LLC now owns 1,514,756 shares of the medical research company's stock valued at $24,963,000 after acquiring an additional 238,288 shares during the period. Finally, Rhumbline Advisers grew its stake in shares of NeoGenomics by 2.4% in the fourth quarter. Rhumbline Advisers now owns 389,003 shares of the medical research company's stock worth $6,411,000 after acquiring an additional 9,098 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Price Performance

NeoGenomics stock traded up $0.16 during trading hours on Wednesday, hitting $9.91. 1,284,184 shares of the stock were exchanged, compared to its average volume of 957,797. NeoGenomics, Inc. has a 12 month low of $8.05 and a 12 month high of $19.12. The business's 50-day moving average is $10.02 and its two-hundred day moving average is $13.55. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. The stock has a market capitalization of $1.27 billion, a P/E ratio of -15.98 and a beta of 1.41.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.05). The business had revenue of $172.00 million for the quarter, compared to analyst estimates of $173.40 million. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. Equities research analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on NEO. The Goldman Sachs Group cut their target price on shares of NeoGenomics from $17.00 to $15.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Bank of America reduced their target price on shares of NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a research note on Wednesday, February 19th. Piper Sandler lowered their price target on NeoGenomics from $21.00 to $18.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Needham & Company LLC cut their price target on NeoGenomics from $19.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday, February 19th. Finally, Benchmark lowered NeoGenomics from a "buy" rating to a "hold" rating in a report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, NeoGenomics presently has an average rating of "Moderate Buy" and a consensus target price of $19.30.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.